Inhalation Sciences: Rights issue outcome - Redeye

Redeye comments on ISAB’s rights issue outcome, which was subscribed to approximately 23% in total. However, as the rights issue was guaranteed up to 80%, the company receives around SEK13.7m before issue-relating costs (cSEK3.5m). As we already anticipated a capital raising, the outcome does not render any changes in our fair value range with a base case of SEK17.

Länk till analysen i sin helhet: https://www.redeye.se/research/907612/inhalation-sciences-rights-issue-outcome?utm_source=finwire&utm_medium=RSS